RxDoctor Payments DataLook up a doctor →

Rodney Hillis, MD

Neurology · Gonzales, LANPI 1336138494

Payments from drug & device makers

$16,670in general payments, 2019–2025

Across 951 payments — averaging $17.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • UCB, Inc.$2K
  • Teva Pharmaceuticals USA, Inc.$1K
  • SK Life Science, Inc.$899
  • Lilly USA, LLC$895
  • Pfizer$862
  • plus $9K from 41 others

What the payments were for

  • Speaking & faculty fees$1601%
  • Food & beverage$16,06496%
  • Education$4453%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$16,670 in reported general payments places this provider in the 80th percentile of 225 neurology providers in Louisiana.

See all neurology providers in Louisiana

Medicare billing

Part B allowed, 2024
$43,402
Medicare patients
135
Services billed
1,325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate17$80,099
UbrelvyUbrogepant41$56,826
QuliptaAtogepant45$52,312
Emgality PenGalcanezumab-Gnlm34$30,413
RytaryCarbidopa/Levodopa21$30,003
Nurtec OdtRimegepant Sulfate20$24,267
Aimovig AutoinjectorErenumab-Aooe23$22,169
NamzaricMemantine Hcl/Donepezil Hcl31$16,064
Oxtellar XrOxcarbazepine11$7,449
Rivastigmine14$5,210
Carbidopa-LevodopaCarbidopa/Levodopa102$3,738
Memantine Hcl173$3,529
Galantamine ErGalantamine Hbr28$3,215
Gabapentin182$2,719
Levetiracetam ErLevetiracetam26$2,295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Namzaric$2,184$125,202117 claims
Acadia Pharmaceuticals IncNuplazid$854$80,09917 claims
Amneal Pharmaceuticals LLCRytary$203$30,00321 claims
PfizerNurtec Odt$862$24,26720 claims
Supernus Pharmaceuticals, Inc.Oxtellar Xr$846$7,44911 claims
Upsher-smith Laboratories LLCTopiramate$152$59254 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 225 neurology providers in Louisiana.

Other neurology in Gonzales

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →